DaVita (DVA)
Technical, fundamental, and sentiment analysis with recent related videos.
DVA rates Neutral overall. The fundamental read is bearish: the company passes 6 of 9 quality tests on the Piotroski F-Score; balance sheet is flagged Distress (Altman Z = 1.63); revenue is growing about 5.6% per year; net income is growing about 12.9% per year. The technical picture is bullish: price is 4.9% above the 200-day moving average; 1.7% above the 50-day; the 50/200 relationship is in a Golden cross. Sentiment is neutral (composite 52/100), based on 8 news articles from recent coverage.
Revenue 3-year avg +5.6%. Net income 3-year avg +12.9%.
Price vs 20DMA +1.9%. RSI 51.8. Bollinger state: Inside Bands.
Composite score 52/100 from the AI judge, based on 8 news items, 0 television segments, and 0 videos.
Latest Market Read
DaVita’s badge mix is split: Fundamental is Bearish even though revenue averaged 5.6 percent per year over three years, because net income averaged 12.9 percent per year but shows a weakening trend. Technical is Bullish, price sits 1.9 percent above the 20-day moving average (20-day moving average), the Relative Strength Index (RSI), a momentum reading, is 51.8, and price is inside the Bollinger Bands (a volatility channel). Sentiment is Neutral at 52/100. The overall rating is Neutral, reflecting conflicting fundamentals and technical strength.
Recent news: GDELT (Global Database of Events, Language, and Tone) and Internet Archive TV coverage show mixed headlines: analysts expect double-digit Q3 earnings growth while DaVita touts clinical momentum, backing the HHS Kidney Care National Plan and presenting seven studies at ASN Kidney Week 2026, and shares have rallied to $183.64. Offsetting those items, management trimmed full-year guidance after mixed profitability amid reimbursement and payer-mix pressure, and the company agreed to a class-action settlement up to $15M over a 2025 ransomware incident. Recent videos called out weakness in U.S. dialysis revenue as a near-term driver of share weakness.